34 results on '"Scheule, Ronald K."'
Search Results
2. Efficacy of Enzyme and Substrate Reduction Therapy with a Novel Antagonist of Glucosylceramide Synthase for Fabry Disease.
- Author
-
Ashe, Karen M., Budman, Eva, Bangari, Dinesh S., Siegel, Craig S., Nietupski, Jennifer B., Bing Wang, Desnick, Robert J., Scheule, Ronald K., Leonard, John P., Cheng, Seng H., and Marshall, John
- Abstract
Fabry disease, an X-linked glycosphingolipid storage disorder, is caused by the deficient activity of α-galactosidase A (α-Gal A). This results in the lysosomal accumulation in various cell types of its glycolipid substrates, including globotriaosylceramide (GL-3) and lysoglobotriaosylceramide (globotriaosyl lysosphingolipid, lyso-GL-3), leading to kidney, heart, and cerebrovascular disease. To complement and potentially augment the current standard of care, biweekly infusions of recombinant α-Gal A, the merits of substrate reduction therapy (SRT) by selectively inhibiting glucosylceramide synthase (GCS) were examined. Here, we report the development of a novel, orally available GCS inhibitor (Genz-682452) with pharmacological and safety profiles that have potential for treating Fabry disease. Treating Fabry mice with Genz-682452 resulted in reduced tissue levels of GL-3 and lyso-GL-3 and a delayed loss of the thermal nociceptive response. Greatest improvements were realized when the therapeutic intervention was administered to younger mice before they developed overt pathology. Importantly, as the pharmacologic profiles of α-Gal A and Genz-682452 are different, treating animals with both drugs conferred the greatest efficacy. For example, because Genz-682452, but not α-Gal A, can traverse the blood–brain barrier, levels of accumulated glycosphingolipids were reduced in the brain of Genz-682452–treated but not α-Gal A–treated mice. These results suggest that combining substrate reduction and enzyme replacement may confer both complementary and additive therapeutic benefits in Fabry disease. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
3. Dysregulation of Multiple Facets of Glycogen Metabolism in a Murine Model of Pompe Disease.
- Author
-
Taylor, Kristin M., Meyers, Elizabeth, Phipps, Michael, Kishnani, Priya S., Cheng, Seng H., Scheule, Ronald K., and Moreland, Rodney J.
- Subjects
- *
GLYCOGEN storage disease type II , *ETIOLOGY of diseases , *GLUCOSIDASES , *CHILD mortality , *ENZYME metabolism , *BIOSYNTHESIS , *CARBOHYDRATE metabolism , *LABORATORY mice - Abstract
Pompe disease, also known as glycogen storage disease (GSD) type II, is caused by deficiency of lysosomal acid α-glucosidase (GAA). The resulting glycogen accumulation causes a spectrum of disease severity ranging from a rapidly progressive course that is typically fatal by 1 to 2 years of age to a slower progressive course that causes significant morbidity and early mortality in children and adults. The aim of this study is to better understand the biochemical consequences of glycogen accumulation in the Pompe mouse. We evaluated glycogen metabolism in heart, triceps, quadriceps, and liver from wild type and several strains of GAA−/− mice. Unexpectedly, we observed that lysosomal glycogen storage correlated with a robust increase in factors that normally promote glycogen biosynthesis. The GAA−/− mouse strains were found to have elevated glycogen synthase (GS), glycogenin, hexokinase, and glucose-6-phosphate (G-6-P, the allosteric activator of GS). Treating GAA−/− mice with recombinant human GAA (rhGAA) led to a dramatic reduction in the levels of glycogen, GS, glycogenin, and G-6-P. Lysosomal glycogen storage also correlated with a dysregulation of phosphorylase, which normally breaks down cytoplasmic glycogen. Analysis of phosphorylase activity confirmed a previous report that, although phosphorylase protein levels are identical in muscle lysates from wild type and GAA−/− mice, phosphorylase activity is suppressed in the GAA−/− mice in the absence of AMP. This reduction in phosphorylase activity likely exacerbates lysosomal glycogen accumulation. If the dysregulation in glycogen metabolism observed in the mouse model of Pompe disease also occurs in Pompe patients, it may contribute to the observed broad spectrum of disease severity. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
4. Systemic Delivery of a Glucosylceramide Synthase Inhibitor Reduces CNS Substrates and Increases Lifespan in a Mouse Model of Type 2 Gaucher Disease.
- Author
-
Cabrera-Salazar, Mario A., DeRiso, Matthew, Bercury, Scott D., Lingyun Li, Lydon, John T., Weber, William, Pande, Nilesh, Cromwell, Mandy A., Copeland, Diane, Leonard, John, Cheng, Seng H., Scheule, Ronald K., and Silman, Israel
- Subjects
- *
ENZYMES , *ENZYME deficiency , *GLYCOSYLCERAMIDASE , *BRAIN , *LABORATORY mice , *NEUROLOGICAL disorders - Abstract
Neuropathic Gaucher disease (nGD), also known as type 2 or type 3 Gaucher disease, is caused by a deficiency of the enzyme glucocerebrosidase (GC). This deficiency impairs the degradation of glucosylceramide (GluCer) and glucosylsphingosine (GluSph), leading to their accumulation in the brains of patients and mouse models of the disease. These accumulated substrates have been thought to cause the severe neuropathology and early death observed in patients with nGD and mouse models. Substrate accumulation is evident at birth in both nGD mouse models and humans affected with the most severe type ofthe disease. Current treatment of non-nGD relies on the intravenous delivery of recombinant human glucocerebrosidase to replace the missing enzyme or the administration of glucosylceramide synthase inhibitors to attenuate GluCer production. However, the currently approved drugs that use these mechanisms do not cross the blood brain barrier, and thus are not expected to provide a benefit for the neurological complications in nGD patients. Here we report the successful reduction of substrate accumulation and CNS pathology together with a significant increase in lifespan after systemic administration of a novel glucosylceramide synthase inhibitor to a mouse model of nGD. To our knowledge this is the first compound shown to cross the blood brain barrier and reduce substrates in this animal model while significantly enhancing its lifespan. These results reinforce the concept that systemically administered glucosylceramide synthase inhibitors could hold enhanced therapeutic promise for patients afflicted with neuropathic lysosomal storage diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
5. Iminosugar-based inhibitors of glucosylceramide synthase prolong survival but paradoxically increase brain glucosylceramide levels in Niemann–Pick C mice
- Author
-
Nietupski, Jennifer B., Pacheco, Joshua J., Chuang, Wei-Lien, Maratea, Kimberly, Li, Lingyun, Foley, Joseph, Ashe, Karen M., Cooper, Christopher G.F., Aerts, Johannes M.F.G., Copeland, Diane P., Scheule, Ronald K., Cheng, Seng H., and Marshall, John
- Subjects
- *
NEURODEGENERATION , *NIEMANN-Pick diseases , *IMINOSUGARS , *GLUCOSYLCERAMIDES , *ENZYME inhibitors , *LABORATORY mice , *GLYCOSPHINGOLIPIDS , *GENETIC mutation - Abstract
Abstract: Niemann Pick type C (NPC) disease is a progressive neurodegenerative disease caused by mutations in NPC1 or NPC2, the gene products of which are involved in cholesterol transport in late endosomes. NPC is characterized by an accumulation of cholesterol, sphingomyelin and glycosphingolipids in the visceral organs, primarily the liver and spleen. In the brain, there is a redistribution of unesterified cholesterol and a concomitant accumulation of glycosphingolipids. It has been suggested that reducing the aberrant lysosomal storage of glycosphingolipids in the brain by a substrate reduction therapy (SRT) approach may prove beneficial. Inhibiting glucosylceramide synthase (GCS) using the iminosugar-based inhibitor miglustat (NB-DNJ) has been reported to increase the survival of NPC mice. Here, we tested the effects of Genz-529468, a more potent iminosugar-based inhibitor of GCS, in the NPC mouse. Oral administration of Genz-529468 or NB-DNJ to NPC mice improved their motor function, reduced CNS inflammation, and increased their longevity. However, Genz-529468 offered a wider therapeutic window and better therapeutic index than NB-DNJ. Analysis of the glycolipids in the CNS of the iminosugar-treated NPC mouse revealed that the glucosylceramide (GL1) but not the ganglioside levels were highly elevated. This increase in GL1 was likely caused by the off-target inhibition of the murine non-lysosomal glucosylceramidase, Gba2. Hence, the basis for the observed effects of these inhibitors in NPC mice might be related to their inhibition of Gba2 or another unintended target rather than a result of substrate reduction. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
6. Systemic Administration of AAV8-α-galactosidase A Induces Humoral Tolerance in Nonhuman Primates Despite Low Hepatic Expression.
- Author
-
Nietupski, Jennifer B, Hurlbut, Gregory D, Ziegler, Robin J, Chu, Qiuming, Hodges, Bradley L, Ashe, Karen M, Bree, Mark, Cheng, Seng H, Gregory, Richard J, Marshall, John, and Scheule, Ronald K
- Subjects
- *
GALACTOSE , *SEROTYPES , *PROTEINS , *BILIARY tract , *MESSENGER RNA - Abstract
In mice, liver-restricted expression of lysosomal enzymes from adeno-associated viral serotype 8 (AAV8) vectors results in reduced antibodies to the expressed proteins. To ask whether this result might translate to patients, nonhuman primates (NHPs) were injected systemically with AAV8 encoding α-galactosidase A (α-gal). As in mice, sustained expression in monkeys attenuated antibody responses to α-gal. However, this effect was not robust, and sustained α-gal levels were 1-2 logs lower than those achieved in male mice at the same vector dose. Because our mouse studies had shown that antibody levels were directly related to expression levels, several strategies were evaluated to increase expression in monkeys. Unlike mice, expression in monkeys did not respond to androgens. Local delivery to the liver, immune suppression, a self-complementary vector and pharmacologic approaches similarly failed to increase expression. While equivalent vector copies reached mouse and primate liver and there were no apparent differences in vector form, methylation or deamination, transgene expression was limited at the mRNA level in monkeys. These results suggest that compared to mice, transcription from an AAV8 vector in monkeys can be significantly reduced. They also suggest some current limits on achieving clinically useful antibody reduction and therapeutic benefit for lysosomal storage diseases using a systemic AAV8-based approach. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
7. Distribution of acid sphingomyelinase in rodent and non-human primate brain after intracerebroventricular infusion
- Author
-
Ziegler, Robin J., Salegio, Ernesto A., Dodge, James C., Bringas, John, Treleaven, Christopher M., Bercury, Scott D., Tamsett, Thomas J., Shihabuddin, Lamya, Hadaczek, Piotr, Fiandaca, Massimo, Bankiewicz, Krystof, and Scheule, Ronald K.
- Subjects
- *
LYSOSOMAL storage diseases , *NIEMANN-Pick diseases , *BRAIN physiology , *CENTRAL nervous system , *CEREBROSPINAL fluid , *ENZYME-linked immunosorbent assay , *IMMUNOHISTOCHEMISTRY , *LABORATORY mice - Abstract
Abstract: One treatment approach for lysosomal storage diseases (LSDs) is the systemic infusion of recombinant enzyme. Although this enzyme replacement is therapeutic for the viscera, many LSDs have central nervous system (CNS) components that are not adequately treated by systemic enzyme infusion. Direct intracerebroventricular (ICV) infusion of a high concentration of recombinant human acid sphingomyelinase (rhASM) into the CNS over a prolonged time frame (hours) has shown therapeutic efficacy in a mouse model of Niemann–Pick A (NP/A) disease. To evaluate whether such an approach would translate to a larger brain, rhASM was infused into the lateral ventricles of both rats and Rhesus macaques, and the resulting distribution of enzyme characterized qualitatively and quantitatively. In both species, ICV infusion of rhASM resulted in parenchymal distribution of enzyme at levels that were therapeutic in the NP/A mouse model. Enzyme distribution was global in nature and exhibited a relatively steep gradient from the cerebrospinal fluid compartment to the inner parenchyma. Additional optimization of an ICV delivery approach may provide a therapeutic option for LSDs with neurologic involvement. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
8. Iminosugar-Based Inhibitors of Glucosylceramide Synthase Increase Brain Glycosphingolipids and Survival in a Mouse Model of Sandhoff Disease.
- Author
-
Ashe, Karen M., Bangari, Dinesh, Li, Lingyun, Cabrera-Salazar, Mario A., Bercury, Scott D., Nietupski, Jennifer B., Cooper, Christopher G. F., Aerts, Johannes M. F. G., Lee, Edward R., Copeland, Diane P., Cheng, Seng H., Scheule, Ronald K., and Marshall, John
- Subjects
- *
BRAIN physiology , *IMINOSUGARS , *GLUCOSYLCERAMIDES , *GLYCOSPHINGOLIPIDS , *LABORATORY mice , *BLOOD-brain barrier , *RESPONSE inhibition , *TAY-Sachs disease , *CENTRAL nervous system , *ENZYME inhibitors , *SANDHOFF disease - Abstract
The neuropathic glycosphingolipidoses are a subgroup of lysosomal storage disorders for which there are no effective therapies. A potential approach is substrate reduction therapy using inhibitors of glucosylceramide synthase (GCS) to decrease the synthesis of glucosylceramide and related glycosphingolipids that accumulate in the lysosomes. Genz-529468, a blood-brain barrier-permeant iminosugar-based GCS inhibitor, was used to evaluate this concept in a mouse model of Sandhoff disease, which accumulates the glycosphingolipid GM2 in the visceral organs and CNS. As expected, oral administration of the drug inhibited hepatic GM2 accumulation. Paradoxically, in the brain, treatment resulted in a slight increase in GM2 levels and a 20-fold increase in glucosylceramide levels. The increase in brain glucosylceramide levels might be due to concurrent inhibition of the non-lysosomal glucosylceramidase, Gba2. Similar results were observed with NB-DNJ, another iminosugar-based GCS inhibitor. Despite these unanticipated increases in glycosphingolipids in the CNS, treatment nevertheless delayed the loss of motor function and coordination and extended the lifespan of the Sandhoff mice. These results suggest that the CNS benefits observed in the Sandhoff mice might not necessarily be due to substrate reduction therapy but rather to off-target effects. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
9. Secreted Gaussia luciferase as a sensitive reporter gene for in vivo and ex vivo studies of airway gene transfer
- Author
-
Griesenbach, Uta, Vicente, Catarina C., Roberts, Megan J., Meng, Cuixiang, Soussi, Samia, Xenariou, Stefania, Tennant, Peter, Baker, Alison, Baker, Eilidh, Gordon, Catherine, Vrettou, Christina, McCormick, Dominique, Coles, Rebecca, Green, Anne-Marie, Lawton, Anna E., Sumner-Jones, Stephanie G., Cheng, Seng H., Scheule, Ronald K., Hyde, Stephen C., and Gill, Deborah R.
- Subjects
- *
LUCIFERASES , *GENETIC transformation , *AIRWAY (Anatomy) , *CLINICAL trials , *GENE therapy , *MESSENGER RNA , *GENE expression , *EPITHELIUM - Abstract
Abstract: The cationic lipid GL67A is one of the more efficient non-viral gene transfer agents (GTAs) for the lungs, and is currently being evaluated in an extensive clinical trial programme for cystic fibrosis gene therapy. Despite conferring significant expression of vector-specific mRNA following transfection of differentiated human airway cells cultured on air liquid interfaces (ALI) cultures and nebulisation into sheep lung in vivo we were unable to detect robust levels of the standard reporter gene Firefly luciferase (FLuc). Recently a novel secreted luciferase isolated from Gaussia princeps (GLuc) has been described. Here, we show that (1) GLuc is a more sensitive reporter gene and offers significant advantages over the traditionally used FLuc in pre-clinical models for lung gene transfer that are difficult to transfect, (2) GL67A-mediated gene transfection leads to significant production of recombinant protein in these models, (3) promoter activity in ALI cultures mimics published in vivo data and these cultures may, therefore, be suitable to characterise promoter activity in a human ex vivo airway model and (4) detection of GLuc in large animal broncho-alveolar lavage fluid and serum facilitates assessment of duration of gene expression after gene transfer to the lungs. In summary, we have shown here that GLuc is a sensitive reporter gene and is particularly useful for monitoring gene transfer in difficult to transfect models of the airway and lung. This has allowed us to validate that GL67A, which is currently in clinical use, can generate significant amounts of recombinant protein in fully differentiated human air liquid interface cultures and the ovine lung in vivo. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
10. Induction of Immune Tolerance to a Therapeutic Protein by Intrathymic Gene Delivery.
- Author
-
Qiuming Chu, Moreland, Rodney J., Lan Gao, Taylor, Kristin M., Meyers, Elizabeth, Cheng, Seng H., and Scheule, Ronald K.
- Subjects
- *
IMMUNOLOGICAL tolerance , *IMMUNE response , *PROTEINS , *GENETIC disorders , *T cells , *MESSENGER RNA - Abstract
The efficacy of recombinant enzyme therapy for genetic diseases is limited in some patients by the generation of a humoral immune response to the therapeutic protein. Inducing immune tolerance to the protein prior to treatment has the potential to increase therapeutic efficacy. Using an AAV8 vector encoding human acid α-glucosidase (hGAA), we have evaluated direct intrathymic injection for inducing tolerance. We have also compared the final tolerogenic states achieved by intrathymic and intravenous injection. Intrathymic vector delivery induced tolerance equivalent to that generated by intravenous delivery, but at a 25-fold lower dose, the thymic hGAA expression level was 10,000-fold lower than the liver expression necessary for systemic tolerance induction. Splenic regulatory T cells (Tregs) were apparent after delivery by both routes, but with different phenotypes. Intrathymic delivery resulted in Tregs with higher FoxP3, TGFβ, and IL-10 mRNA levels. These differences may account for the differences noted in splenic T cells, where only intravenous delivery appeared to inhibit their activation. Our results imply that different mechanisms may be operating to generate immune tolerance by intrathymic and intravenous delivery of an AAV vector, and suggest that the intrathymic route may hold promise for decreasing the humoral immune response to therapeutic proteins in genetic disease indications. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
11. Preexisting Immunity and Low Expression in Primates Highlight Translational Challenges for Liver-directed AAV8-mediated Gene Therapy.
- Author
-
Hurlbut, Gregory D., Ziegler, Robin J., Nietupski, Jennifer B., Foley, Joseph W., Woodworth, Lisa A., Meyers, Elizabeth, Bercury, Scott D., Pande, Nilesh N., Souza, David W., Bree, Mark P., Lukason, Michael J., Marshall, John, Cheng, Seng H., and Scheule, Ronald K.
- Subjects
- *
LIVER diseases , *GENE expression , *PRIMATE physiology , *ADENOVIRUS diseases , *IMMUNOGENETICS , *LABORATORY mice , *IMMUNOGLOBULINS , *GENE therapy , *THERAPEUTICS - Abstract
Liver-directed gene therapy with adeno-associated virus (AAV) vectors effectively treats mouse models of lysosomal storage diseases (LSDs). We asked whether these results were likely to translate to patients. To understand to what extent preexisting anti-AAV8 antibodies could impede AAV8-mediated liver transduction in primates, commonly preexposed to AAV, we quantified the effects of preexisting antibodies on liver transduction and subsequent transgene expression in mouse and nonhuman primate (NHP) models. Using the highest viral dose previously reported in a clinical trial, passive transfer of NHP sera containing relatively low anti-AAV8 titers into mice blocked liver transduction, which could be partially overcome by increasing vector dose tenfold. Based on this and a survey of anti-AAV8 titers in 112 humans, we predict that high-dose systemic gene therapy would successfully transduce liver in >50% of human patients. However, although high-dose AAV8 administration to mice and monkeys with equivalent anti-AAV8 titers led to comparable liver vector copy numbers, the resulting transgene expression in primates was ~1.5-logs lower than mice. This suggests vector fate differs in these species and that strategies focused solely on overcoming preexisting vector-specific antibodies may be insufficient to achieve clinically meaningful expression levels of LSD genes using a liver-directed gene therapy approach in patients. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
12. Substrate Reduction Augments the Efficacy of Enzyme Therapy in a Mouse Model of Fabry Disease.
- Author
-
Marshall, John, Ashe, Karen M., Bangari, Dinesh, McEachern, KerryAnne, Wei-Lien Chuang, Pacheco, Joshua, Copeland, Diane P., Desnick, Robert J., Shayman, James A., Scheule, Ronald K., and Cheng, Seng H.
- Subjects
- *
GLYCOSPHINGOLIPIDS , *SPHINGOLIPIDS , *LABORATORY mice , *ORGANELLES , *KIDNEY diseases , *GAUCHER'S disease - Abstract
Fabry disease is an X-linked glycosphingolipid storage disorder caused by a deficiency in the activity of the lysosomal hydrolase α-galactosidase A (α-gal). This deficiency results in accumulation of the glycosphingolipid globotriaosylceramide (GL-3) in lysosomes. Endothelial cell storage of GL-3 frequently leads to kidney dysfunction, cardiac and cerebrovascular disease. The current treatment for Fabry disease is through infusions of recombinant α-gal (enzyme-replacement therapy; ERT). Although ERT can markedly reduce the lysosomal burden of GL-3 in endothelial cells, variability is seen in the clearance from several other cell types. This suggests that alternative and adjuvant therapies may be desirable. Use of glucosylceramide synthase inhibitors to abate the biosynthesis of glycosphingolipids (substrate reduction therapy, SRT) has been shown to be effective at reducing substrate levels in the related glycosphingolipidosis, Gaucher disease. Here, we show that such an inhibitor (eliglustat tartrate, Genz-112638) was effective at lowering GL-3 accumulation in a mouse model of Fabry disease. Relative efficacy of SRT and ERT at reducing GL-3 levels in Fabry mouse tissues differed with SRT being more effective in the kidney, and ERT more efficacious in the heart and liver. Combination therapy with ERT and SRT provided the most complete clearance of GL-3 from all the tissues. Furthermore, treatment normalized urine volume and uromodulin levels and significantly delayed the loss of a nociceptive response. The differential efficacies of SRT and ERT in the different tissues indicate that the combination approach is both additive and complementary suggesting the possibility of an improved therapeutic paradigm in the management of Fabry disease. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
13. Evaluation of Systemic Follistatin as an Adjuvant to Stimulate Muscle Repair and Improve Motor Function in Pompe Mice.
- Author
-
Foley, Joseph W., Bercury, Scott D., Finn, Patrick, Cheng, Seng H., Scheule, Ronald K., and Ziegler, Robin J.
- Subjects
- *
HYPERTROPHY , *GLYCOGEN storage disease , *GLUCOSIDASES , *MOLECULAR genetics , *MOTOR ability , *FOLLISTATIN , *LABORATORY mice , *GENE therapy - Abstract
Due to the lack of acid α-glucosidase (GAA) activity, Pompe mice develop glycogen storage pathology and progressive skeletal muscle dysfunction with age. Applying either gene or enzyme therapy to reconstitute GAA levels in older, symptomatic Pompe mice effectively reduces glycogen storage in skeletal muscle but provides only modest improvements in motor function. As strategies to stimulate muscle hypertrophy, such as by myostatin inhibition, have been shown to improve muscle pathology and strength in mouse models of muscular dystrophy, we sought to determine whether these benefits might be similarly realized in Pompe mice. Administration of a recombinant adeno-associated virus serotype 8 vector encoding follistatin, an inhibitor of myostatin, increased muscle mass and strength but only in Pompe mice that were treated before 10 months of age. Younger Pompe mice showed significant muscle fiber hypertrophy in response to treatment with follistatin, but maximal gains in muscle strength were achieved only when concomitant GAA administration reduced glycogen storage in the affected muscles. Despite increased grip strength, follistatin treatment failed to improve rotarod performance. These findings highlight the importance of treating Pompe skeletal muscle before pathology becomes irreversible, and suggest that adjunctive therapies may not be effective without first clearing skeletal muscle glycogen storage with GAA. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
14. Inhibition of glycogen biosynthesis via mTORC1 suppression as an adjunct therapy for Pompe disease
- Author
-
Ashe, Karen M., Taylor, Kristin M., Chu, Qiuming, Meyers, Elizabeth, Ellis, Allen, Jingozyan, Varvara, Klinger, Katherine, Finn, Patrick F., Cooper, Christopher G.F., Chuang, Wei-Lien, Marshall, John, McPherson, John M., Mattaliano, Robert J., Cheng, Seng H., Scheule, Ronald K., and Moreland, Rodney J.
- Subjects
- *
GLYCOGEN storage disease type II , *ETIOLOGY of diseases , *GLUCOSIDASES , *GLYCOGEN , *BIOSYNTHESIS , *RAPAMYCIN , *IMMUNOSUPPRESSIVE agents , *THERAPEUTICS - Abstract
Abstract: Pompe disease, also known as glycogen storage disease (GSD) type II, is caused by deficiency of lysosomal acid α-glucosidase (GAA). The resulting glycogen accumulation causes a spectrum of disease severity ranging from a rapidly progressive course that is typically fatal by 1–2years of age to a more slowly progressive course that causes significant morbidity and early mortality in children and adults. Recombinant human GAA (rhGAA) improves clinical outcomes with variable results. Adjunct therapy that increases the effectiveness of rhGAA may benefit some Pompe patients. Co-administration of the mTORC1 inhibitor rapamycin with rhGAA in a GAA knockout mouse reduced muscle glycogen content more than rhGAA or rapamycin alone. These results suggest mTORC1 inhibition may benefit GSDs that involve glycogen accumulation in muscle. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
15. The use of carboxymethylcellulose gel to increase non-viral gene transfer in mouse airways
- Author
-
Griesenbach, Uta, Meng, Cuixiang, Farley, Raymond, Wasowicz, Marguerite Y., Munkonge, Felix M., Chan, Mario, Stoneham, Charlotte, Sumner-Jones, Stephanie G., Pringle, Ian A., Gill, Deborah R., Hyde, Stephen C., Stevenson, Barbara, Holder, Emma, Ban, Hiroshi, Hasegawa, Mamoru, Cheng, Seng H., Scheule, Ronald K., Sinn, Patrick L., McCray, Paul B., and Alton, Eric W.F.W.
- Subjects
- *
VIRAL genetics , *GENETIC transformation , *LABORATORY mice , *VISCOELASTICITY , *PHARMACEUTICAL gels , *GENE expression , *IMMUNOHISTOCHEMISTRY , *GENE therapy - Abstract
Abstract: We have assessed whether viscoelastic gels known to inhibit mucociliary clearance can increase lipid-mediated gene transfer. Methylcellulose or carboxymethylcellulose (0.25–1.5%) was mixed with complexes of the cationic lipid GL67A and plasmids encoding luciferase and perfused onto the nasal epithelium of mice. Survival after perfusion with 1% CMC or 1% MC was 90 and 100%, respectively. In contrast 1.5% CMC was uniformly lethal likely due to the viscous solution blocking the airways. Perfusion with 0.5% CMC containing lipid/DNA complexes reproducibly increased gene expression by approximately 3-fold (n =16, p <0.05). Given this benefit, likely related to increased duration of contact, we also assessed the effect of prolonging contact time of the liposome/DNA complexes by delivering our standard 80μg DNA dose over either approximately 22 or 60min of perfusion. This independently increased gene transfer by 6-fold (n =8, p <0.05) and could be further enhanced by the addition of 0.5% CMC, leading to an overall 25-fold enhancement (n =8, p <0.001) in gene expression. As a result of these interventions CFTR transgene mRNA transgene levels were increased several logs above background. Interestingly, this did not lead to correction of the ion transport defects in the nasal epithelium of cystic fibrosis mice nor for immunohistochemical quantification of CFTR expression. To assess if 0.5% CMC also increased gene transfer in the mouse lung, we used whole body nebulisation chambers. CMC was nebulised for 1h immediately before, or simultaneously with GL67A/pCIKLux. The former did not increase gene transfer, whereas co-administration significantly increased gene transfer by 4-fold (p <0.0001, n =18). This study suggests that contact time of non-viral gene transfer agents is a key factor for gene delivery, and suggests two methods which may be translatable for use in man. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
16. The role of doxorubicin in non-viral gene transfer in the lung
- Author
-
Griesenbach, Uta, Meng, Cuixiang, Farley, Raymond, Gardner, Aaron, Brake, Maresa A., Frankel, Gad M., Gruenert, Dieter C., Cheng, Seng H., Scheule, Ronald K., and Alton, Eric W.F.W.
- Subjects
- *
GENETIC transformation , *DOXORUBICIN , *PULMONARY pharmacology , *CYSTIC fibrosis , *PROTEINS , *CHEMICAL inhibitors , *CANCER chemotherapy - Abstract
Abstract: Proteasome inhibitors have been shown to increase adeno-associated virus (AAV)-mediated transduction in vitro and in vivo. To assess if proteasome inhibitors also increase lipid-mediated gene transfer with relevance to cystic fibrosis (CF), we first assessed the effects of doxorubicin and N-acetyl-l-leucinyl-l-leucinal-l-norleucinal in non-CF (A549) and CF (CFTE29o-) airway epithelial cell lines. CFTE29o- cells did not show a response to Dox or LLnL; however, gene transfer in A549 cells increased in a dose-related fashion (p <0.05), up to approximately 20-fold respectively at the optimal dose (no treatment: 9.3×104 ±1.5×103, Dox: 1.6×106 ±2.6×105, LLnL: 1.9×106 ±3.2×105 RLU/mg protein). As Dox is used clinically in cancer chemotherapy we next assessed the effect of this drug on non-viral lung gene transfer in vivo. CF knockout mice were injected intraperitoneally (IP) with Dox (25–100mg/kg) immediately before nebulisation with plasmid DNA carrying a luciferase reporter gene under the control of a CMV promoter/enhancer (pCIKLux) complexed to the cationic lipid GL67A. Dox also significantly (p <0.05) increased expression of a plasmid regulated by an elongation factor 1α promoter (hCEFI) approximately 8-fold. Although administration of Dox before lung gene transfer may not be a clinically viable option, understanding how Dox increases lung gene expression may help to shed light on intracellular bottle-necks to gene transfer, and may help to identify other adjuncts that may be more appropriate for use in man. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
17. Systemic Insulin-like Growth Factor-1 Reverses Hypoalgesia and Improves Mobility in a Mouse Model of Diabetic Peripheral Neuropathy.
- Author
-
Chu, Qiuming, Moreland, Rod, Yew, Nelson S, Foley, Joseph, Ziegler, Robin, and Scheule, Ronald K
- Subjects
- *
GENE therapy , *DEMYELINATION , *MICE , *NEUROPATHY , *LABORATORY animals , *PREVENTIVE medicine , *PAIN , *HYPERALGESIA , *THERAPEUTICS - Abstract
Peripheral neuropathy is a particularly debilitating complication of both type 1 and type 2 diabetes characterized by sensory and motor neuron damage and decreased circulating levels of insulin-like growth factor 1 (IGF-1). Quite often, an early hyperalgesia is followed by hypoalgesia and muscle weakness. Hypoalgesia can lead to significant morbidity for which there is no current treatment. Hyperglycemic, streptozotocin (STZ)-induced rodent models reproduce these symptoms. We investigated whether increasing systemic IGF-1 could improve neuronal function in hyper- and hypoalgesic STZ-treated mice. Increased circulating levels of IGF-1 were achieved by delivering a plasmid or adeno-associated viral (AAV) vector bearing mouse IGF-1 to the liver. Treating mice in the hyperalgesia stage prevented later hypoalgesia. Treating mice in the hypoalgesia stage reversed existing hypoalgesia. This latter effect could be seen by merely restoring IGF-1 serum levels to normalcy, which was possible to achieve by IGF-1 gene therapy or insulin treatment. Sensory nerve functional correction was seen to be correlated with attenuated Schwann cell vacuolization and demyelination in peripheral sensory nerve fibers. A further increase in serum IGF-1 levels with gene therapy also improved motor function, consistent with the observed prevention of both muscle atrophy and peripheral motor nerve fiber demyelination. These results suggest that the restoration of systemic levels of IGF-1 may prove to be a highly effective therapeutic modality for treating diabetic peripheral neuropathy.Molecular Therapy (2008) 16 8, 1400–1408 doi:10.1038/mt.2008.115 [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
18. In vivo imaging of gene transfer to the respiratory tract
- Author
-
Griesenbach, Uta, Meng, Cuixiang, Farley, Raymond, Cheng, Seng H., Scheule, Ronald K., Davies, Mark H., Wolstenholme-Hogg, Paul C., ten Hove, Willem, van der Hoeven, Paul, Sinn, Patrick L., McCray, Paul B., Inoue, Makoto, Geddes, Duncan M., Hasegawa, Mamoru, Frankel, Gad, Wiles, Siouxsie, and Alton, Eric W.F.W.
- Subjects
- *
RESPIRATORY organs , *GENETIC transformation , *NUCLEIC acids , *MICROBIAL genetics - Abstract
Abstract: Imaging of in vivo gene expression using luciferase expression in various organs has been used for several years. In contrast to other organs, in vivo imaging of the lung, particularly after non-viral gene transfer has not been extensively studied. The aim of this study was to address several questions: (1) Does in vivo light emission correlate with standard tissue homogenate-based luciferase detection in a dose-dependent manner? Recombinant Sendai virus (SeV) transduces airway epithelial cells very efficiently and was used to address this question, (2) Is the sensitivity of the assay sufficient to detect non-viral gene transfer? We treated mice with SeV-Lux vector using our standard “sniffing” protocol, a method that predominantly results in lung deposition. Dose-related in vivo light emission was visible in all animals. Importantly, there was a significant correlation (r >0.90, p <0.0001) between the in vivo and ex vivo assays in both the left and right lung. We next transfected the nasal epithelium via nasal perfusion or the lungs (“sniffing”) of mice with a luciferase plasmid (pCIKLux) complexed to the cationic lipid GL67 (n =25–27/group) and imaged luciferase expression in vivo 24h after transfection. Gene expression was detectable in both organs. Correlation between the in vivo and ex vivo assays was significant (r =0.52, p <0.005) in the left, but not the right lung. The correlation in the nose was weaker (r =0.45, p <0.05). To our knowledge these studies show for the first time that this non-invasive method of assessing pulmonary gene transfer is viable for evaluating non-viral gene transfer agents. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
19. Role of viral hemagglutinin glycosylation in anti-influenza activities of recombinant surfactant protein D.
- Author
-
Hartshorn, Kevan L., Webby, Richard, White, Mitchell R., Tecle, Tesfaldet, Pan, Clark, Boucher, Susan, Moreland, Rodney J., Crouch, Erika C., and Scheule, Ronald K.
- Subjects
- *
HEMAGGLUTININ , *GLYCOSYLATION , *RECOMBINANT proteins , *INFLUENZA A virus , *INFLUENZA - Abstract
Background: Surfactant protein D (SP-D) plays an important role in innate defense against influenza A viruses (IAVs) and other pathogens. Methods: We tested antiviral activities of recombinant human SP-D against a panel of IAV strains that vary in glycosylation sites on their hemagglutinin (HA). For these experiments a recombinant version of human SP-D of the Met11, Ala160 genotype was used after it was characterized biochemically and structurally. Results: Oligosaccharides at amino acid 165 on the HA in the H3N2 subtype and 104 in the H1N1 subtype are absent in collectin-resistant strains developed in vitro and are important for mediating antiviral activity of SP-D; however, other glycans on the HA of these viral subtypes also are involved in inhibition by SP-D. H3N2 strains obtained shortly after introduction into the human population were largely resistant to SP-D, despite having the glycan at 165. H3N2 strains have become steadily more sensitive to SP-D over time in the human population, in association with addition of other glycans to the head region of the HA. In contrast, H1N1 strains were most sensitive in the 1970s-1980s and more recent strains have become less sensitive, despite retaining the glycan at 104. Two H5N1 strains were also resistant to inhibition by SP-D. By comparing sites of glycan attachment on sensitive vs. resistant strains, specific glycan sites on the head domain of the HA are implicated as important for inhibition by SP-D. Molecular modeling of the glycan attachment sites on HA and the carbohydrate recognition domain of SPD are consistent with these observations. Conclusion: Inhibition by SP-D correlates with presence of several glycan attachment sites on the HA. Pandemic and avian strains appear to lack susceptibility to SP-D and this could be a contributory factor to their virulence. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
20. Surfactant Protein-D and Surfactant Inhibit Endotoxin-Induced Pulmonary lnflammation.
- Author
-
Ikegami, Machiko, Scoville, Elizabeth A., Grant, Shawn, Korfhagen, Thomas, Brondyk, William, Scheule, Ronald K., and Whitsett, Jeffrey A.
- Subjects
- *
ENDOTOXINS , *LUNG diseases , *INFLAMMATION , *RECOMBINANT proteins , *RESPIRATORY diseases - Abstract
The article reports on the results of a study of the effect of exogenous recombinant human surfactant protein-D (rhSP-D) on protection of the adult mouse lung from lipopolysaccharide (LPS)-induced and lipoteichoic acid (LTA)-induced injury. A description of study methods is presented. The study concluded that intratracheal rhSP-D inhibited inflammation induced by intratracheal LPS and LTA instillation in the lung.
- Published
- 2007
- Full Text
- View/download PDF
21. Timing of Therapeutic Intervention Determines Functional and Survival Outcomes in a Mouse Model of Late Infantile Batten Disease.
- Author
-
Cabrera-Salazar, Mario A., Roskelley, Eric M., Jie Bu, Hodges, Bradley L., Yew, Nelson, Dodge, James C., Shihabuddin, Lamya S., Sohar, Istvan, Sleat, David E., Scheule, Ronald K., Davidson, Beverly L., Cheng, Seng H., Lobel, Peter, and Passini, Marco A.
- Subjects
- *
NEURONAL ceroid-lipofuscinosis , *PEPTIDASE , *ADENOVIRUSES , *NEURONS , *GENETIC mutation - Abstract
Classical late infantile neuronal ceroid lipofuscinosis (cLINCL) is a monogenic disorder caused by the loss of tripeptidyl peptidase 1 (TPP1) activity as a result of mutations in CLN2. Absence of TPP1 results in lysosomal storage with an accompanying axonal degeneration throughout the central nervous system (CNS), which leads to progressive neurodegeneration and early death. In this study, we compared the efficacies of pre- and post-symptomatic injections of recombinant adeno-associated virus (AAV) for treating the cellular and functional abnormalities of CLN2 mutant mice. Intracranial injection of AAV1-hCLN2 resulted in widespread human TPP1 (hTPP1) activity in the brain that was 10–100-fold above wild-type levels. Injections before disease onset prevented storage and spared neurons from axonal degeneration, reflected by the preservation of motor function. Furthermore, the majority of CLN2 mutant mice treated pre-symptomatically lived for at least 330 days, compared with a median survival of 151 days in untreated CLN2 mutant controls. In contrast, although injection after disease onset ameliorated lysosomal storage, there was evidence of axonal degeneration, motor function showed limited recovery, and the animals had a median lifespan of 216 days. These data illustrate the importance of early intervention for enhanced therapeutic benefit, which may provide guidance in designing novel treatment strategies for cLINCL patients.Molecular Therapy (2007) 15 10, 1782–1788. doi:10.1038/sj.mt.6300249 [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
22. Inefficient cationic lipid-mediated siRNA and antisense oligonucleotide transfer to airway epithelial cells in vivo.
- Author
-
Griesenbach, Uta, Kitson, Chris, Garcia, Sara Escudero, Farley, Raymond, Singh, Charanjit, Somerton, Luci, Painter, Hazel, Smith, Rbecca L., Gill, Deborah R., Hyde, Stephen C., Yu-Hua Chow, Hu, Jim, Gray, Mike, Edbrooke, Mark, Ogilvie, Varrie, MacGregor, Gordon, Scheule, Ronald K, Cheng, Seng H., Caplen, Natasha J., and Alton, Eric W. F. W.
- Subjects
- *
SMALL interfering RNA , *OLIGONUCLEOTIDES , *RESPIRATORY organs , *CELLS , *EPITHELIUM , *LABORATORY mice - Abstract
Background: The cationic lipid Genzyme lipid (GL) 67 is the current "gold-standard" for in vivo lung gene transfer. Here, we assessed, if GL67 mediated uptake of siRNAs and asODNs into airway epithelium in vivo. Methods: Anti-lacZ and ENaC (epithelial sodium channel) siRNA and asODN were complexed to GL67 and administered to the mouse airway epithelium in vivo Transfection efficiency and efficacy were assessed using real-time RT-PCR as well as through protein expression and functional studies. In parallel in vitro experiments were carried out to select the most efficient oligonucleotides. Results: In vitro, GL67 efficiently complexed asODNs and siRNAs, and both were stable in exhaled breath condensate. Importantly, during in vitro selection of functional siRNA and asODN we noted that asODNs accumulated rapidly in the nuclei of transfected cells, whereas siRNAs remained in the cytoplasm, a pattern consistent with their presumed site of action. Following in vivo lung transfection siRNAs were only visible in alveolar macrophages, whereas asODN also transfected alveolar epithelial cells, but no significant uptake into conducting airway epithelial cells was seen. SiRNAs and asODNs targeted to β-galactosidase reduced βgal mRNA levels in the airway epithelium of K18-lacZ mice by 30% and 60%, respectively. However, this was insufficient to reduce protein expression. In an attempt to increase transfection efficiency of the airway epithelium, we increased contact time of siRNA and asODN using the in vivo mouse nose model. Although highly variable and inefficient, transfection of airway epithelium with asODN, but not siRNA, was now seen. As asODNs more effectively transfected nasal airway epithelial cells, we assessed the effect of asODN against ENaC, a potential therapeutic target in cystic fibrosis; no decrease in ENaC mRNA levels or function was detected. Conclusion: This study suggests that although siRNAs and asODNs can be developed to inhibit gene expression in culture systems and certain organs in vivo, barriers to nucleic acid transfer in airway epithelial cells seen with large DNA molecules may also affect the efficiency of in vivo uptake of small nucleic acid molecules. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
23. Local Delivery of a Viral Vector Mitigates Neutralization by Antiviral Antibodies and Results in Efficient Transduction of Rabbit Liver
- Author
-
Hodges, Bradley L., Taylor, Kristin M., Chu, Qiuming, Scull, Samantha E., Serriello, Rebecca G., Anderson, Scott C., Wang, Fei, and Scheule, Ronald K.
- Subjects
- *
BILIARY tract , *IMMUNOGLOBULINS , *MICROBIAL genetics , *GENETIC transformation - Abstract
Abstract: Antiviral antibodies within the human population remain a barrier to the effective clinical use of viral gene transfer vectors. We have asked whether local, balloon catheter-mediated delivery of a viral vector to the rabbit liver using a hepatic vein might mitigate the neutralizing effects of antiviral antibodies. We have compared directly the ability of adenovirus (Ad2) encoding nuclear-localized β-galactosidase to infect the rabbit liver after local and systemic delivery in both the presence and the absence of defined anti-Ad2 antibody titers. In naive rabbits, local delivery resulted in higher β-galactosidase expression compared to systemic delivery. In the presence of passively administered anti-Ad2 antibodies, local delivery resulted in expression levels that were comparable to those obtained in naive rabbits by systemic delivery. Local delivery also resulted in the majority of expression originating from hepatocytes, even in passively immunized animals, a result that could not be duplicated using the systemic approach. Since systemic delivery of adenovirus in naive animal models results in transgene expression levels often regarded as therapeutic, these results predict that local hepatic vein delivery of a viral vector is a clinically practical approach to mitigate neutralizing antiviral antibodies and generate therapeutic levels of transgene expression. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
24. Transient siRNA-Mediated Attenuation of Liver Expression from an α-Galactosidase a Plasmid Reduces Subsequent Humoral Immune Responses to the Transgene Product in Mice
- Author
-
Chu, Qiuming, Joseph, Macy, Przybylska, Malgorzata, Yew, Nelson S., and Scheule, Ronald K.
- Subjects
- *
BILIARY tract , *MOBILE genetic elements , *GENETIC engineering , *IMMUNOGLOBULINS - Abstract
Abstract: Hepatocytes are an effective depot for protein production from gene therapy vectors. However, when gene transfer vectors or their delivery induces hepatic inflammation, adaptive immune responses against the transgene product can ensue. In BALB/c mice, hydrodynamic delivery of a CMV-driven plasmid DNA (pDNA) bearing human α-galactosidase A (αgal) to the liver generated antibodies against αgal. This humoral immune response was more robust in a transgenic knockout for αgal, the Fabry mouse. The antibody response could be attenuated in both mouse strains by using a promoter more restricted to hepatocytes. In an attempt to reduce further the humoral responses to αgal, expression from the transgene was attenuated by using siRNA during the period of initial delivery-associated liver inflammation. In both mouse models and with both promoters, codelivering an αgal siRNA resulted in a 2 log decrease in initial expression that then increased over the next few weeks to levels generated by the pDNA alone. This strategy led to both attenuated antibodies and an immune status approximating “tolerance” to αgal. Importantly, in the Fabry mouse, an αgal siRNA together with a hepatocyte-restricted promoter gave minimal anti-αgal antibodies and profound tolerance, suggesting that such an approach might have clinical utility for genetic diseases. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
25. Long-term Transgene Expression from Plasmid DNA Gene Therapy Vectors Is Negatively Affected by CpG Dinucleotides
- Author
-
Hodges, Bradley L., Taylor, Kristin M., Joseph, Macy F., Bourgeois, Sarah A., and Scheule, Ronald K.
- Subjects
- *
GENE therapy , *GENETIC engineering , *HEMOPHILIA , *BLOOD diseases - Abstract
CpG-reduced, CMV-based plasmid DNA constructs encoding human α-galactosidase A and factor IX were injected into C57Bl/6, BALB/c, and CD1 mice using hydrodynamics-based delivery of plasmid DNA (pDNA), and gene expression was monitored for 6 months. Linearized and supercoiled pDNAs were compared for their abilities to support long-term expression and to generate immune responses to the transgene product. In all mouse strains supercoiled CpG-reduced pDNA encoding α-galactosidase A and factor IX generated higher and more sustained levels of circulating gene product than their supercoiled CpG-replete analogs. Linearizing supercoiled CpG-reduced pDNA did not significantly increase levels of circulating gene product beyond levels supercoiled CpG-reduced pDNA could achieve. Linearizing supercoiled CpG-replete pDNA vectors significantly increased expression compared to their supercoiled CpG-replete analogs, but the increase was short-lived or subtherapeutic. Regardless of vector, liver depot expression did not elicit significant antibody responses to human α-galactosidase A or factor IX. Taken together, these data suggest that a clinically acceptable hydrodynamics-based approach targeting the liver combined with CpG-reduced pDNA vectors may represent a viable option for individuals with hemophilia, a lysosomal storage disease, or other disease in which prolonged depot expression of a therapeutic protein from the liver is desirable. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
26. Endostatin gene transfection using a cationic lipid: advantages of transfection before tumor cell inoculation and repeated transfection.
- Author
-
Yano, Motoki, Nakashima, Yoshiaki, Kobayashi, Yoshihiro, Mizuno, Kotaro, Konishi, Akamitsu, Sasaki, Hidefumi, Fukai, Ichiro, Scheule, Ronald K., and Fujii, Yoshitaka
- Subjects
- *
INTRAVENOUS therapy , *TUMOR suppressor genes , *LIPIDS , *GENE transfection , *ANIMAL experimentation , *VIRAL genetics , *CANCER treatment - Abstract
Intravenous endostatin gene transfection results in tumor suppression in a murine pulmonary metastasis model. We transfected the endostatin gene at different times, in order to achieve an optimal protective effect. pST2-Endo encoding murine endostatin was injected in a complex with cationic lipid. Pulmonary metastases were caused by intravenous injection of murine fibrosarcoma cells. Mice were observed for 14 days following fibrosarcoma cell inoculation (FSI). In the study groups, the animals were transfected with pST2-Endo at three different times: 2 days before and 3 and 7 days after FSI. In the group transfected with pST2-Endo 2 days before FSI, the weights of the lungs and tumor-occupied area ratio were significantly less than in the other groups. Significant inhibition of tumor neovascularization was documented by means of CD31 immunohistochemistry. The effect of repeated endostatin transfection on survival after FSI was determined. Animals repeatedly transfected with the endostatin gene survived significantly longer than the groups treated with a single endostatin gene transfection. A stable endostatin-expressing fibrosarcoma transfectant was created and tested for migration and invasion. Compared with controls, endostatin expression reduced migration and invasion by 15%. It is concluded that endostation gene transfection before FSI and repeated transfection thereafter results in significant tumor suppression. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
27. Contribution of Toll-like Receptor 9 Signaling to the Acute Inflammatory Response to Nonviral Vectors
- Author
-
Zhao, Hongmei, Hemmi, Hiraoki, Akira, Shizuo, Cheng, Seng H., Scheule, Ronald K., and Yew, Nelson S.
- Subjects
- *
GENE therapy , *LIPIDS , *PLASMIDS , *DNA - Abstract
Immunostimulatory CpG motifs have been implicated as a major contributor to the acute inflammatory response associated with nonviral vectors, most prominently seen after systemic delivery of cationic lipid–plasmid DNA (pDNA) complexes. We have shown previously that complexes containing pDNA vectors that have been largely depleted of CpG motifs have significantly reduced acute toxicity when delivered systemically. However, several CpGs remain in these vectors and the toxicity is not negligible, especially at higher doses of complex. To determine the maximal reduction in the acute toxic response that could be achieved by eliminating CpG signaling, we injected cationic lipid–pDNA complexes into transgenic mice that are deficient in Toll-like receptor 9 (TLR9), which is the receptor that recognizes immunostimulatory CpG motifs. We observed significantly decreased adverse hematological changes and liver damage in TLR9−/− mice compared to normal mice and increased survival at higher doses of complex. However, a pronounced loss of lymphocytes and platelets was still observed in the TLR9−/− mice at higher doses. We also measured the toxicity in normal mice of systemically delivered complexes containing non-CpG oligonucleotides. Although serum transaminase levels were reduced, a loss of lymphocytes and platelets akin to that seen in the TLR9−/− mice was observed. Taken together, these findings suggest that signaling through TLR9 contributes to the majority but not all of the toxic responses associated with systemic delivery of cationic lipid–pDNA complexes. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
28. Tumor Treatment with Complexes of Cationic Lipid and Noncoding Plasmid DNA Results in the Induction of Cytotoxic T Cells and Systemic Tumor Elimination
- Author
-
Siders, William M., Vergillis, Kristin, Johnson, Carrie, Scheule, Ronald K., and Kaplan, Johanne M.
- Subjects
- *
TUMOR treatment , *PLASMIDS , *CELLULAR immunity - Abstract
We have demonstrated recently that treatment of established peritoneal mesothelial tumors with complexes composed of cationic lipid and noncoding plasmid DNA (pNull) results in the inhibition of tumor growth accompanied by the induction of a tumor-specific cellular immune response. In this study, treatment of mice bearing intraperitoneal (i.p.) M3 melanoma tumors with i.p. injections of lipid/pNull complex was found to inhibit tumor growth and induce the development of a cytolytic response against several M3 melanoma-associated antigens. Depletion of CD8+ T cells, as opposed to natural killer (NK) or CD4+ T cells, essentially abrogated the therapeutic effect of lipid+pNull complex, thus supporting the involvement of cytotoxic CD8+ T cells in the antitumor response. The antitumor effect of lipid/pNull complex was maximal following delivery into a tumor-bearing compartment. For example, i.p. delivery of complex was more effective than intravenous (i.v.) or subcutaneous (s.c.) treatment of i.p. M3 tumors. In addition, i.v. injection of complex displayed therapeutic activity against lung metastases caused by i.v. injection of tumor cells, and intratumoral injection of complex into solid s.c. tumors caused regression in most animals. Importantly, the immune response induced by local treatment of tumors with complex also offered systemic protection against tumor cells at distal sites, as illustrated by the eradication of both peritoneal tumors and lung metastases in mice treated with complex delivered i.p. Treatment with lipid/pNull complex, therefore, represents an attractive immune-based treatment modality that could potentially be applied to many tumor types. [Copyright &y& Elsevier]
- Published
- 2002
- Full Text
- View/download PDF
29. CpG-Depleted Plasmid DNA Vectors with Enhanced Safety and Long-Term Gene Expression in Vivo
- Author
-
Yew, Nelson S., Zhao, Hongmei, Przybylska, Malgorzata, Wu, I-Huan, Tousignant, Jennifer D., Scheule, Ronald K., and Cheng, Seng H.
- Subjects
- *
PLASMID genetics , *INFLAMMATION , *BLOOD diseases - Abstract
Systemic delivery of cationic lipid–plasmid DNA (pDNA) complexes induces an acute inflammatory response with adverse hematologic changes and liver damage. Immunostimulatory CpG motifs in the pDNA are known to contribute substantially to this response. Here we constructed a pDNA vector (pGZB) that has been depleted of 80% of the CpG motifs present in the original vector. Compared with the unmodified vector, systemic administration of pGZB induced considerably fewer changes in blood parameters, reduced levels of inflammatory cytokines, and decreased liver damage. Despite the extensive sequence modifications within pGZB, there were still robust levels of transgene expression. Furthermore, in contrast to the transient expression observed from the unmodified vector, we observed sustained or increasing expression for up to 49 days from pGZB in the lung and liver of immunocompetent BALB/c mice. Studies adding CpG motifs in trans or in cis indicate that the reduced CpG content of pGZB was the major determinant for its persistent expression. This combination of decreased toxicity and sustained expression suggests that CpG-depleted pDNA vectors can greatly improve the safety and efficacy of synthetic gene delivery systems. [Copyright &y& Elsevier]
- Published
- 2002
- Full Text
- View/download PDF
30. 531. Balloon Catheter-Mediated Hepatic Vein Delivery of a Viral Vector Mitigates Neutralization by Anti-Viral Antibodies and Results in Efficient Transduction of Rabbit Liver
- Author
-
Hodges, Bradley L., Taylor, Kristin M., Chu, Qiuming, Scull, Samantha E., Serriello, Rebecca G., Anderson, Scott C., and Scheule, Ronald K.
- Subjects
- *
HEPATIC veins , *GENETIC transformation - Abstract
An abstract of the article "Balloon Catheter-Mediated Hepatic Vein Delivery of a Viral Vector Mitigates Neutralization by Anti-Viral Antibodies and Results in Efficient Transduction of Rabbit Liver," by Bradley L. Hodgesand colleagues is presented.
- Published
- 2005
- Full Text
- View/download PDF
31. Antisense oligonucleotide-mediated suppression of muscle glycogen synthase 1 synthesis as an approach for substrate reduction therapy of Pompe disease.
- Author
-
Clayton, Nicholas P., Nelson, Carol A., Weeden, Timothy, Taylor, Kristin M., Moreland, Rodney J., Scheule, Ronald K., Leger, Andrew J., Phillips, Lucy, Cheng, Seng H., and Wentworth, Bruce M.
- Subjects
- *
GLYCOGEN storage disease type II , *ANTISENSE peptides , *OLIGONUCLEOTIDES , *IMMUNOSUPPRESSION , *GLYCOGEN synthase kinase , *THERAPEUTICS - Published
- 2015
- Full Text
- View/download PDF
32. 893. Second Generation Gene Therapy Vector for Classical Late Infantile Neuronal Ceroid Lipofuscinosis.
- Author
-
Cabrera-Salazar, Mario A., Hodges, Bradley L., Yew, Nelson S., Jie Bu, Fidler, Jonathan A., Roskelley, Eric M., Scheule, Ronald K., Sleat, David E., Lobel, Peter, Cheng, Seng H., and Passini, Marco A.
- Subjects
- *
NEURONAL ceroid-lipofuscinosis , *NEURODEGENERATION , *NEURONS , *GENE therapy , *PATHOLOGY - Abstract
Classical late infantile neuronal ceroid lipofuscinosis (cLINCL) is a neurodegenerative disorder that results from the loss of tripeptidyl peptidase I (TPP1) enzyme activity. Patients with cLINCL possess seizures that are frequently associated with blindness, exhibit cognitive and behavioral deficits that are progressive, and death by 7–20 years of age. Accumulation of autofluorescent storage material is a cardinal feature of the disease, as well as axonal degeneration and loss of cortical neurons. A recent study by our group in a knockout mouse model of cLINCL showed that recombinant AAV2 or AAV5 significantly reduced autofluorescent storage and curvilinear bodies in cells of the brain. Reversal of pathology was restricted to injected and nearby structures at a dose of 2.0 e11 genome copies (gc)/ml. To further evaluate AAV gene therapy, a codon-optimized synthetic human CLN2 cDNA was engineered, packaged into AAV1 capsids (AAV1-hCLN2), concentrated to a high titer (3.3 e12 gc/ml), and injected into the CLN2 (−/−) thalamus of one hemisphere. At 1 month post-injection, brain homogenates of the injection site contained TTP1 enzyme activity that was 15-fold higher than corresponding regions of untreated CLN2 (+/+) mice. TPP1 activity was also observed in the rostral and caudal regions of injected hemisphere, and in the contralateral hemisphere at levels 2-fold higher than CLN2 (+/+) controls. These data demonstrate that the AAV1 vector is capable of producing widespread and high levels of TPP1 activity in vivo. A cohort of 4-week old CLN2 (−/−) mice were then injected with AAV1-hCLN2 into multiple structures of the right (striatum, hippocampus, cerebellum) and left (motor cortex, thalamus, medulla) hemispheres to investigate global reversal of pathology, functional recovery, and extension of lifespan. The results of this experiment including behavioral testing and survival data will be presented.Molecular Therapy (2006) 13, S344–S344; doi: 10.1016/j.ymthe.2006.08.982 [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
33. 217. Comparison of Hepatic Vein and Peripheral Vein Delivery of an AAV2/8 Vector Encoding Human a-Galactosidase A to Rhesus Macaques.
- Author
-
Hodges, Bradley L., Chu, Qiuming, Nietupski, Jennifer B., Ashe, Karen M., Taylor, Kristin M., Ziegler, Robin J., Cheng, Seng H., Marshall, John, and Scheule, Ronald K.
- Subjects
- *
RHESUS monkeys , *IMMUNOGLOBULINS , *CERCOPITHECIDAE , *HEMODYNAMICS , *LYSOSOMAL storage diseases - Abstract
In murine models of lysosomal storage diseases, sustained hepatocyte-restricted expression and secretion of the therapeutic enzyme is capable of correcting the peripheral pathology associated with the storage product. For example, systemic delivery of a recombinant AAV8 vector encoding human alpha-galactosidase A to Fabry mice resulted in complete clearance of the glycosphingolipid storage product in peripherally affected tissues when sustained serum alpha-galactosidase A levels were in excess of 1 ug/ml. In humans, transient blood levels of human FIX have been obtained after hepatocyte transduction with an AAV2 vector. The abbreviatedexpression was attributed to cytotoxic lymphocyte (CTL) recognition of viral capsid epitopes on the transduced cells. In view of these potential immune-based limitations on expression, we have asked whether we could generate prolonged circulating levels of human alpha-galactosidase A following delivery of an AAV2/8 vector encoding human alpha-galactosidase A under control of a hepatocyte-restricted promoter to immune suppressed rhesus macaques. We have compared systemic delivery using a peripheral vein approach and local delivery using a hepatic vein approach that was developed in a rabbit model. The hepatic vein approach uses a balloon catheter to isolate a lobe of the liver and block blood flow into the vena cava. We then flush the vasculature of the lobe retrograde to blood flow to reduce the concentration of any resident anti-viral antibodies and to allow the viral vector to “dwell” within the lobe for a defined period after delivery. A three month immune suppression regime was used to blunt any neutralizing immune responses to virally-transduced cells or human alpha-galactosidase A. After removing immune suppression, animals will be challenged with purified human alpha- galactosidase A to assess their degree of tolerance to this foreign protein. Although this experiment is not yet complete, we will present up-to-date expression and toxicity data comparing the two delivery techniques.Molecular Therapy (2006) 13, S84–S84; doi: 10.1016/j.ymthe.2006.08.242 [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
34. 695. Low-Frequency Ultrasound Increases Non-Viral Lung Gene Transfer.
- Author
-
Stefania Xenariou, Hai-Dong Liang, Griesenbach, Uta, Jie Zhu, Farley, Raymond, Somerton, Lucinda, Singh, Charanjit, Jeffery, Peter K., Scheule, Ronald K., Cheng, Seng H., Geddes, Duncan M., Blomley, Martin, and Alton, Eric W. F. W.
- Subjects
- *
GENETIC transformation , *MOBILE genetic elements , *CELL membranes , *LUNGS , *MICROBIAL genetics - Abstract
We have previously shown that high-frequency (1 MHz) ultrasound (U/S) increases naked plasmid DNA (pDNA) gene transfer in the mouse lung and that this effect requires microbubbles (Optison) to be present in the formulation. Here, we assessed low-frequency (30–35 kHz) U/S, in an attempt to further increase non- viral gene delivery to the lung in vivo. The potential advantages of lowering U/S frequency include: a) increased cavitation, the mechanism responsible for the formation of transient pores on cell membranes and b) enhanced penetration of U/S energy into the lung, by reducing wave scattering and heat losses. Cationic lipid GL67 (GL67)/pDNA (80 μg/100 μl), polyethylenimine (PEI)/pDNA (20 μg/100 μl) and naked pDNA (100 μg/100 μl) were delivered to Balb/ c mice via intranasal instillation. Low-frequency U/S (30–35 kHz, 0.07 or 0.1 Mpa, 10 min) was then applied onto the chest and back. Sonoporation did not enhance GL67/pDNA and PEI/pDNA gene transfer. However, U/S exposure at 0.1 Mpa, but not at 0.07 Mpa, increased naked pDNA transfection approximately 4-fold (pDNA: 5.9±1.2 RLU/mg protein, pDNA + 0.1 Mpa: 22.6±3.8 RLU/mg protein, p<0.05, n=7–8). Importantly, low-frequency U/S increased lung gene transfer in the absence of microbubbles. Addition of Optison did not further enhance this effect, due to its inhibitory effects on non-viral lung gene transfer (pDNA + Optison: 0.4±0.1 RLU/mg protein, pDNA + Optison + 0.1 Mpa: 2.5±0.7 RLU/mg protein, n=7–8). Haemorrhage, a common U/S-induced side-effect, was also assessed and increased with pressure in a dose-dependent manner. Interestingly, haemorrhage occurred throughout the lung, indicating that U/S may penetrate deep into the tissue. We have, thus, established for the first time that low-frequency sonoporation can enhance non-viral gene delivery to the mouse lung in vivo.Molecular Therapy (2006) 13, S269–S269; doi: 10.1016/j.ymthe.2006.08.773 [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.